A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients With Presbyopia

Trial Profile

A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients With Presbyopia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jul 2017

At a glance

  • Drugs AGN 190584 (Primary) ; Oxymetazoline (Primary)
  • Indications Presbyopia
  • Focus Therapeutic Use
  • Sponsors Allergan
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 13 Aug 2017 to 6 Jan 2018.
    • 18 Jul 2017 Planned primary completion date changed from 13 Aug 2017 to 6 Jan 2018.
    • 17 May 2017 Planned End Date changed from 1 Jul 2017 to 13 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top